Kengrexal

Cangrelor Tetrasodium, the active ingredient in Kengrexal, is a P2Y12 receptor antagonist presented as a solution for injection for intravenous use. It is employed to prevent thrombotic complications during percutaneous coronary intervention and to provide antiplatelet therapy in patients with acute coronary syndromes undergoing invasive procedures.\n\nGNH India supplies Kengrexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for this injectable product globally.

Kengrexal, a P2Y12 receptor antagonist, is used in cardiovascular interventions to inhibit platelet aggregation.\n\n- Percutaneous coronary intervention (PCI): reduces risk of procedural thrombotic events.\n- Acute coronary syndrome undergoing invasive procedures: provides rapid antiplatelet effect during treatment.\n- Cardiac catheterization procedures: offers immediate platelet inhibition to support anticoagulation strategy.

Cangrelor Tetrasodium may be associated with several adverse reactions, ranging from common to serious.\n\nCommon Side Effects:\n- Bleeding at the injection site: mild to moderate\n- Mild hypotension: transient drop in blood pressure\n- Nausea: occasional gastrointestinal upset\n- Headache: mild to moderate intensity\n\nSerious or Rare Side Effects:\n- Severe or uncontrolled bleeding: may require medical intervention\n- Allergic reactions including anaphylaxis: rare but potentially life‑threatening\n- Thrombocytopenia: significant drop in platelet count\n- Myocardial infarction: rare cardiac event

When using Kengrexal, several precautions should be observed to minimize risks.\n- Renal impairment: monitor renal function and adjust therapy as needed.\n- Hepatic impairment: use with caution and observe for increased bleeding.\n- Concurrent anticoagulants: increased bleeding risk, consider dose adjustment.\n- History of bleeding disorders: avoid use or ensure close monitoring.\n- Upcoming surgery or invasive procedures: discontinue prior to the procedure as recommended.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cangrelor Tetrasodium can interact with other medications, affecting bleeding risk or drug efficacy.\n\nMajor Interactions (Avoid):\n- Co‑administration with other P2Y12 inhibitors: additive antiplatelet effect may cause severe bleeding.\n- Use with glycoprotein IIb/IIIa inhibitors: markedly increased bleeding risk.\n- Strong CYP3A4 inducers (if applicable): may reduce antiplatelet effect.\n\nModerate Interactions (Monitor Closely):\n- Heparin or low‑molecular‑weight heparin: additive anticoagulant effect, monitor coagulation parameters.\n- Warfarin or direct oral anticoagulants: heightened bleeding tendency, adjust monitoring.\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased gastrointestinal bleeding risk.